Burich相关文献与解析，生知库 | 链接生命科学的每一步

Apsley, Abner T; Domico, Emma R; Verbiest, Max A; Brogan, Carly A; Buck, Evan R; Burich, Andrew J; Cardone, Kathleen M; Stone, Wesley J; Anisimova, Maria; Vandenbergh, David J

发表日期：2023

文献求助收藏

The Vave campaign: impact evaluation of a cancer awareness raising multi-media campaign in Samoa

Vave 活动：萨摩亚癌症意识提升多媒体宣传活动的影响评估

期刊:Health Promotion International

影响因子:2.4

doi:10.1093/heapro/daac021

Sofija, Ernesta; Harris, Neil; Cuesta-Briand, Beatriz; Spratling, Tim; Burich, Shelley

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases

非小细胞肺癌中驱动基因突变谱及循环肿瘤DNA分析的临床意义：超过8000例病例分析

期刊:Cancer

影响因子:5.1

doi:10.1002/cncr.32876

Mack, Philip C; Banks, Kimberly C; Espenschied, Carin R; Burich, Rebekah A; Zill, Oliver A; Lee, Christine E; Riess, Jonathan W; Mortimer, Stefanie A; Talasaz, AmirAli; Lanman, Richard B; Gandara, David R

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

通过对非小细胞肺癌进行全面的基因组分析，鉴定出多种EGFR 20号外显子插入突变及伴随的分子改变。

期刊:Journal of Thoracic Oncology

影响因子:20.8

doi:10.1016/j.jtho.2018.06.019

Riess, Jonathan W; Gandara, David R; Frampton, Garrett M; Madison, Russell; Peled, Nir; Bufill, Jose A; Dy, Grace K; Ou, Sai-Hong Ignatius; Stephens, Philip J; McPherson, John D; Lara, Primo N Jr; Burich, Rebekah A; Ross, Jeffrey S; Miller, Vincent A; Ali, Siraj M; Mack, Philip C; Schrock, Alexa B

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

不可逆突变选择性 EGFR 酪氨酸激酶抑制剂奥希替尼在携带 EGFR 外显子 20 插入的 NSCLC 中的抗肿瘤活性

期刊:Molecular Cancer Therapeutics

影响因子:5.3

doi:10.1158/1535-7163.MCT-17-0758

Nicolas Floc'h #, Matthew J Martin #, Jonathan W Riess #, Jonathan P Orme, Anna D Staniszewska, Ludovic Ménard, Maria Emanuela Cuomo, Daniel J O'Neill, Richard A Ward, M Raymond V Finlay, Darren McKerrecher, Mingshan Cheng, Daniel P Vang, Rebekah A Burich, James G Keck, David R Gandara, Philip C Mac

肿瘤

发表日期：2018

文献求助收藏

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer

MET 抑制剂 INC-280 与表皮生长因子受体抑制剂厄洛替尼联合治疗非小细胞肺癌的临床前评估

期刊:Clinical Lung Cancer

影响因子:3.3

doi:10.1016/j.cllc.2016.11.006

Matthew S Lara, William S Holland, Danielle Chinn, Rebekah A Burich, Primo N Lara Jr, David R Gandara, Karen Kelly, Philip C Mack

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy

多维替尼治疗抗血管内皮生长因子疗法后病情进展患者的II期研究

期刊:Cancer Treatment and Research Communications

影响因子:2.4

doi:10.1016/j.ctarc.2016.12.002

Semrad, Thomas J; Kim, Edward J; Tanaka, Michael S; Sands, Jacob; Roberts, Chris; Burich, Rebekah A; Li, Yu; Gandara, David R; Lara, Primo Jr; Mack, Philip C

心血管

发表日期：2017

文献求助收藏

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform

通过整合的患者来源异种移植平台，将肿瘤基因组学与患者预后联系起来

期刊:Clinical Lung Cancer

影响因子:3.3

doi:10.1016/j.cllc.2015.03.001

Gandara, David R; Mack, Philip C; Bult, Carol; Li, Tianhong; Lara, Primo N Jr; Riess, Jonathan W; Astrow, Stephanie H; Gandour-Edwards, Regina; Cooke, David T; Yoneda, Ken Y; Moore, Elizabeth H; Pan, Chong-Xian; Burich, Rebekah A; David, Elizabeth A; Keck, James G; Airhart, Susan; Goodwin, Neal; de Vere White, Ralph W; Liu, Edison T

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

吉西他滨和厄洛替尼在局部晚期或转移性胰腺癌中的药效学分离：治疗和生物标志物结果

期刊:International Journal of Clinical Oncology

影响因子:2.4

doi:10.1007/s10147-014-0730-2

Thomas Semrad, Afsaneh Barzi, Heinz-Josef Lenz, Irene M Hutchins, Edward J Kim, I-Yeh Gong, Michael Tanaka, Laurel Beckett, William Holland, Rebekah A Burich, Leslie Snyder-Solis, Philip Mack, Primo N Lara Jr

Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model

奥培米芬和 4-羟基奥培米芬在 MTag.Tg 转基因小鼠模型中有效预防和治疗乳腺癌

期刊:Menopause-The Journal of the North American Menopause Society

影响因子:2.8

doi:10.1097/gme.0b013e318223e82a

Rebekah A Burich, Neelima Rakesh Mehta, Gregory T Wurz, Jamie Lee McCall, Brittany E Greenberg, Katie E Bell, Stephen M Griffey, Michael W DeGregorio

A novel hypervariable variable number tandem repeat in the dopamine transporter gene (SLC6A3)

多巴胺转运蛋白基因（SLC6A3）中一种新型高变可变数目串联重复序列

The Vave campaign: impact evaluation of a cancer awareness raising multi-media campaign in Samoa

Vave 活动：萨摩亚癌症意识提升多媒体宣传活动的影响评估

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases

非小细胞肺癌中驱动基因突变谱及循环肿瘤DNA分析的临床意义：超过8000例病例分析

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

通过对非小细胞肺癌进行全面的基因组分析，鉴定出多种EGFR 20号外显子插入突变及伴随的分子改变。

Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

不可逆突变选择性 EGFR 酪氨酸激酶抑制剂奥希替尼在携带 EGFR 外显子 20 插入的 NSCLC 中的抗肿瘤活性

Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer

MET 抑制剂 INC-280 与表皮生长因子受体抑制剂厄洛替尼联合治疗非小细胞肺癌的临床前评估

Phase II Study of Dovitinib in Patients Progressing on Anti-Vascular Endothelial Growth Factor Therapy

多维替尼治疗抗血管内皮生长因子疗法后病情进展患者的II期研究

Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform

通过整合的患者来源异种移植平台，将肿瘤基因组学与患者预后联系起来

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

吉西他滨和厄洛替尼在局部晚期或转移性胰腺癌中的药效学分离：治疗和生物标志物结果

Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model

奥培米芬和 4-羟基奥培米芬在 MTag.Tg 转基因小鼠模型中有效预防和治疗乳腺癌